Patent Allowance Granted for ALA-002 Composition by US Patent and Trademark Office
Retrieved on:
Wednesday, March 27, 2024
Research, Social anxiety, Composition, Brain, NCE, IPON, Environment, Patent, Incidence, Patient, University, Hyperthermia, Autism spectrum, MDXX, The central science, United States patent law, General Population (album), Test, IP, OTC, Spectrum, MDMA, Intellectual property, FDA, ASD, Food, Pharmaceutical industry
Preclinical testing has shown that the administration of ALA-002 results in significantly lowered incidence of hyperthermia, the major adverse event elicited by racemic generic MDMA.
Key Points:
- Preclinical testing has shown that the administration of ALA-002 results in significantly lowered incidence of hyperthermia, the major adverse event elicited by racemic generic MDMA.
- PharmAla’s patent application included in-vivo experimental animal data, which is generally held to be stronger evidence than computational, or in-silico, modeling.
- The Company intends to pursue its own clinical research with the novel composition, either alone or with an out-licensing partner.
- “We are incredibly pleased that USPTO has issued an allowance for the granting of the Composition of Matter patent for ALA-002.